An announcement today was made that the investigational once-daily oral teriflunomide reduced relapses compared to placebo in 1088 patients with relapsing MS in the TEMSO trial.

The FDA has granted a priority review for this experimental oral treatment for relapsing forms of multiple sclerosis.